Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03137758 is registered in ClinicalTrials.gov with Pellficure Pharmaceuticals, Inc as lead sponsor.

NCT NCT03137758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03137758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Pellficure Pharmaceuticals, Inc
Phase
Phase 1
Overall status
Terminated
Start date
July 24, 2017
Completion date
September 17, 2019
Enrollment
12 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer